Who are CG Oncology's investors?

CG Oncology's investors include Decheng Capital, Foresite Capital, Longitude Capital, Palm Drive Capital, RA Capital, TCG Crossover, ACORN BIOVENTURES, Ally Bridge Group and 2 more.

CG Oncology

NASDAQ: CGON

Incorporated in Delaware · 10 known investors

Find your way into CG Oncology

Paths you didn't know you had: your email and LinkedIn already hold routes to the CG Oncology team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer. The company's approach combines engineered viral immunotherapy with potential combination therapies to improve patient quality of life.

Biotech Healthtech Medical Devices

Founders & leadership

Arthur Kuan Chairman and CEOArthur Kuan is Chairman, President and Chief Executive Officer of CG Oncology, which develops oncolytic immunotherapy for urologic cancer.

Investors · 10

Decheng Capitallisted by Decheng CapitalMenlo Park

How we know: Decheng Capital's portfolio page · the S-1 prospectus · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the S-1 prospectus · funding news · the VCSheet dataset · Not right? Tell us

Palm Drive Capitallisted by Palm Drive CapitalNew York · $500K – $5M

How we know: Palm Drive Capital's portfolio page · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · funding news · Not right? Tell us

TCG Crossoverlisted by TCG CrossoverPalo Alto

ACORN BIOVENTURESreportedNew York

How we know: funding news · Not right? Tell us

Ally Bridge GroupreportedNew York

How we know: funding news · Not right? Tell us

Camford CapitalreportedMenlo Park

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

ORI CapitalreportedHong Kong

How we know: the S-1 prospectus · funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries ENov 2022
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline - CG Oncology |cgoncology.com · Nov 2022

Frequently asked questions

What does CG Oncology do?: CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer. The company's approach combines engineered viral immunotherapy with potential combination therapies to improve patient quality of life.
Who are CG Oncology's investors?: CG Oncology's investors include Decheng Capital, Foresite Capital, Longitude Capital, Palm Drive Capital, RA Capital, TCG Crossover, ACORN BIOVENTURES, Ally Bridge Group and 2 more.